Method for treating prostatic diseases

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: the present innovation deals with developing new medicinal preparations for treating urogenital diseases. The suggested preparation for treating prostatic diseases designed as a suppository that contains the complex of bioregulatory peptides of cattle prostate as a powder with the content of water-soluble peptides being 20%, not less and the foundation, moreover, antimicrobial preparation being the antibiotic or anti-viral preparation, or anti-protozoan preparation, or the mixture of antibiotic and anti-protozoan preparation taken at 1:1 ratio, or the mixture of anti-viral and anti-protozoan preparation taken at 1:1 ratio and the foundation at the following ratio of the components, g/suppository: complex of bioregulatory peptides of cattle prostate 0.05-0.4; antimicrobial preparation 0.7, not more; the foundation - sufficient quantity to obtain the suppository of 2.15-2.35 g weight. The suggested preparation in the form of suppository is of high level of organotropic activity and high level of antimicrobial action that enables to implement etiotropic and pathogenetic therapy of bacterial prostatitis. The innovation provides the action upon an agent and all pathological processes in the affected organ. The innovation enables to treat bacterial prostatic inflammation and that of functionally associated organs.

EFFECT: higher efficiency of therapy.

4 cl, 132 ex, 32 tbl

 

The invention relates to medicine and the pharmaceutical industry, in particular to the creation of new medicines for the treatment of diseases of the genitourinary system.

Currently, diseases of the prostate occupy a significant place among urological pathology, tend to increase and are becoming increasingly social significance.

Prostatitis is one of the most common among men of urological diseases.

Important role in the development of prostate play previous or current infection, which in addition to involvement in the pathological process of the urethra can complicate the course of the inflammatory process in the prostate.

Treatment of patients with prostatitis aimed at eliminating infection and normalize the functions of the prostate gland. In a comprehensive treatment program that usually includes antibiotic therapy, therapy drugs that improve vascular tone, physiotherapy, bracing means, as well as surgical intervention.

Currently, one of the promising directions in the treatment of prostatitis is the use of the funds directed to the stimulation of nonspecific reactivity of the organism, in particular the use of drugs of natural origin. To ensure about the of tacita used herbal medicines (herbal medicine), enzymes and immune modulators, in particular cytomedines.

Cytomedines - peptides with molecular weight of 1000-10000 daltons. They have the ability to restore disturbed as a result of a pathological process or aging specific functions of those organs and tissues that serve as source material for their preparation.

Significant is the presence of the examined peptides immunomoduliruyushhih properties.

In addition, cytometery not have molecular possess narrow specificity resulting from their use drugs do not have antigenic properties and, as a consequence of side effects that allows relatively free to vary the dosage and course of treatment.

One of the members of the class of citomedines are bioregulatory peptides of the prostate gland of cattle (cattle) with a content of water-soluble peptides of at least 20%.

Pharmacological action of complex bioregulatory peptides of the prostate gland of cattle allows pathogenetic therapy of diseases of the prostate and functionally related bodies, as bioregulatory peptides have an organotropic action on the prostate.

Known formulations of various drugs, containing a complex of bioregulatory peptides is predstatelnoy gland of cattle.

One such means is the drug "Reveron", which is an extract from the prostate gland of adult animals, are exempt from androgenic and estrogenic hormones and proteins. The drug is used in the initial phase of benign prostatic hyperplasia and chronic nonspecific prostatitis, comes in the form of injections. The disadvantage of this drug is prolonged course of treatment and the propensity for allergic reactions "Reveron" contraindicated (Mashkovsky PPM Medicines. M, Medicine, 1994, Vol.2, s).

Known rectal treatment for prostatitis various etiologies, containing a biologically active substance liquid purified extract of the prostate gland of cattle and excipients: gelatin, glycerin and sodium carbonate-bicarbonate buffer (patent RF №2152204 on "Rectal tool"). This drug promotes increased circulation and improved outflow of secretions from the prostate gland for the correction of violations that accompany any changes in circulation and trophic prostate cancer, i.e. it expresses an organotropic properties, but this drug does not solve the problem of eradication of the infection.

It is also known rectal treatment for chronic prostatitis various etiologies containing complex is bioregulatory peptides of the prostate gland of cattle, which is used as a liquid concentrate of purified extract of the prostate gland of cattle and component activityinterferon-man, stabilizer and excipients: gelatin, glycerin and sodium carbonate-bicarbonate buffer (patent RF №2160114 on "Rectal treatment for chronic prostatitis"). This drug is intended for treatment of chronic prostatitis different etiology, occurring against the background of immunodeficiency. The tool itself is a complex drug that contains two biologically active products, which makes it multifunctional, but it does not solve the problem of eradication of the infection.

Closest to the claimed means of essential features is a drug for the treatment of diseases of the prostate "Vitaprost" (patent RF №2112504 on the "tool for the treatment of diseases of the prostate "Vitaprost").

A well-known tool is a suppository that contains a set of bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% and a basis. The tool has an organotropic action on the prostate and is used for the treatment of diseases of the prostate and functionally connected to the adjacent organs. However, the level of organotrophic activity funds is limited to the content of complex bioregulatory peptides of the prostate gland of cattle, which is due process. In addition, the agent has no antimicrobial effect.

The objective of the invention is the creation of complex medicines in the form of a suppository for the treatment of diseases of the prostate, with a high level organotropic activity and a high level of antimicrobial action.

The technical result of the proposed use of funds is to increase its organotropic activity and a significant increase of antimicrobial action, allowing etiotropic and pathogenetic therapy of bacterial prostatitis.

The problem is solved, we offer a tool that contains a set of bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% and a basis, according to the invention it further comprises an antimicrobial agent, representing an antibiotic or an antiviral agent or antibacterial agent, or a mixture of antibiotic and Antiprotozoal drugs are taken in the ratio 1:1, or a mixture of antiviral and antibacterial means ot the ies in the ratio of 1:1, in the following ratio of components, g on one candle:

Complex bioregulatory peptides prostate cattle 0,05-0,4

Antimicrobial agent is not more than 0.7

The basis is sufficient to obtain the suppository mass of 2.15 to 2.35,

It is preferable that as antibiotic use antibiotic from the group of fluoroquinolones, such as lomefloxacin, ofloxacin, or from the group of penicillins, such as amoxicillin, ampicillin, or from the group of cephalosporins such as cefaclor, cefixime, or from the group of tetracyclines, such as doxycycline, tetracycline, or from the class of sulfonamides such as co-trimoxazole.

It is preferable that as antiviral agents are used, such as ribavirin, lamivudine.

It is preferable that as Antiprotozoal drugs use antibacterial drug from the group of nitroimidazoles, such as metronidazole, Ornidazole, tinidazole.

It is preferable that as the basis for using any pharmaceutically acceptable base, which allows to obtain a suppository, for example witepsol, tallow, cocoa butter.

Introduction to the proposed remedy at the same time complex bioregulatory peptides prostate cattle and antimicrobial agent allows you to get the tool in the form of a suppository:

with you is okim level organotropic activity the increase is achieved, on the one hand, due to the increase in the composition of the quantitative content of the complex bioregulatory peptides of the prostate gland of cattle, and on the other hand, due to the synergistic effect is due to the fact that the antimicrobial agent accelerates the delivery of bioregulatory peptides of the prostate gland of cattle to the affected organ, as antimicrobial agent reduces swelling and improves blood rheology;

- with a high level of antimicrobial action, which is achieved, on the one hand, due to the introduction of the antimicrobial agent with bactericidal and bacteriostatic action on a wide range of pathogens, and on the other hand, due to the synergistic effect due to the fact that bioregulatory peptides of the prostate, improving microcirculation, neutrophase and immune processes in the tissues of the prostate, contribute to more effective absorption and enhancing the action of antimicrobial drugs.

Thus, the proposed tool is complex, influenced by both the pathogen and all pathological processes in the affected organ, which leads to more effective treatment of bacterial inflammation of the prostate and functionally related organs.

The content of therapeutic substances into the candle mass is (of 2.15 to 2.35 g) is established experimentally. Maintenance of the complex bioregulatory peptides of less than 0.05 g per candle does not provide the desired therapeutic action.

Maintenance of the complex bioregulatory peptides more than 0.4 g and antimicrobial agent more than 0.7 g complicates the manufacturing process of suppozitornoj mass.

The method of obtaining the proposed tools.

Separately prepare concentrates of the complex bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% and antimicrobial agent with a part of the base, taken from the basis of 1:1. The resulting concentrates are mixed with the remaining basis at a temperature of 38-40°C. a Homogeneous mass is poured in blister packaging from a film of polyvinylchloride and cool, which further allows to obtain suppositories that meet the requirements of the State Pharmacopoeia, XI edition.

Below are examples of manufacturing the offered means in the form of suppositories.

Example 1.

Melt the basis of witepsol in the amount of UAH 1,862 kg at a temperature of 55-65°under stirring. Complex bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% in the number of 0,596 kg is mixed with part of the molten core of witepsol taken in soo is wearing 1:1. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. Powder antibiotic - lomefloxacin in the amount 1,042 kg is mixed with part of the molten core of witepsol taken in sootnoshenii 1:1. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. The resulting concentrates are loaded into the remaining witepsol under stirring to obtain a homogeneous mass. The finished mass is poured into the cell from a polyvinylchloride film and cool.

Get suppositories weight of 2.35 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.4 g

Lomefloxacin - 0.7 g

The basis of the rest.

Example 2.

Carried out analogously to example 1, but with the following quantities of components: complex bioregulatory peptides prostate cattle - of 0.081 kg, lomefloxacin - 0,813 kg basics - 2,606 kg

Get suppositories weighing 2.15 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.05 g

Lomefloxacin - 0.5 g

The basis of the rest.

Example 3.

Carried out analogously to example 1, but with the following quantities of components: complex bioregulatory peptides prostate cattle - 0,622 kg,lomefloxacin - 0,777 kg basics - 2,101 kg

Get suppositories weighing 2.25 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.4 g

Lomefloxacin - 0.5 g

The basis of the rest.

Example 4.

Carried out analogously to example 1, but with the following quantities of components: complex bioregulatory peptides prostate cattle - 0.077 kg, lomefloxacin - 1,088 kg basics - 2,335 kg

Get suppositories weighing 2.25 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.05 g

Lomefloxacin - 0.7 g

The basis of the rest.

Example 5.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains ofloxacin, and as the basis - tallow.

Example 6.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains ofloxacin, and as the basis - tallow.

Example 7.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains ofloxacin, and as the basis - tallow.

Example 8.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains ofloxacin, and as the basis - tallow.

Example 9.

Carried out analogously to example 1 only as an antimicrobial agent in the composition contains amoxicillin, and as the basis for the cocoa butter.

Example 10.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains amoxicillin, and as the basis for the cocoa butter.

Example 11.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains amoxicillin, and as the basis for the cocoa butter.

Example 12.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains amoxicillin, and as the basis for the cocoa butter.

Example 13.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains ampicillin.

Example 14.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains ampicillin.

Example 15.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains ampicillin.

Example 16.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains ampicillin.

Example 17.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains cefaclor.

Example 18.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains cefaclor.

Example 19.

Carried out analogously to example 3, only as an antimicrobial agent with the Tav contains cefaclor.

Example 20.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains cefaclor.

Example 21.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains cefixime.

Example 22.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains cefixime.

Example 23.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains cefixime.

Example 24.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains cefixime.

Example 25.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains doxycycline.

Example 26.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains doxycycline.

Example 27.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains doxycycline.

Example 28.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains doxycycline.

Example 29.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contain tetracycline.

Example 30.

Carried out analogously to example 2, only as an antimicrobial agent composition contains tetracy the lean.

Example 31.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contain tetracycline.

Example 32.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contain tetracycline.

Example 33.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains co-trimoxazole.

Example 34.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains co-trimoxazole.

Example 35.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains co-trimoxazole.

Example 36.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains co-trimoxazole.

Example 37.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contain ribavirin.

Example 38.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contain ribavirin.

Example 39.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contain ribavirin.

Example 40.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contain ribavirin.

Example 41.

Carried out analogously to example 1, only as an antimicrobial agent in the composition which contains lamivudine.

Example 42

Carried out analogously to example 2, only as an antimicrobial agent in the composition contain lamivudine.

Example 43.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contain lamivudine.

Example 44.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contain lamivudine.

Example 45.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains metronidazole.

Example 46.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains metronidazole.

Example 47.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains metronidazole.

Example 48.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains metronidazole.

Example 49.

Carried out analogously to example 1, only as an antimicrobial agent in the composition contains tinidazole.

Example 50.

Carried out analogously to example 2, only as an antimicrobial agent in the composition contains tinidazole.

Example 51.

Carried out analogously to example 3, only as an antimicrobial agent in the composition contains tinidazole.

Example 52.

Carried out analogously to example 4, only as an antimicrobial agent in the composition contains t is nidazole.

Example 53.

Melt the basis of witepsol in the amount of UAH 1,862 kg at a temperature of 55-65°under stirring. Complex bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% in the number of 0,596 kg is mixed with part of the molten core of witepsol taken in 1:1 ratio. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. Powder antibiotic - lomefloxacin in the number 0,521 kg is mixed with part of the molten core of witepsol taken in 1:1 ratio. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. Antibacterial agent - metronidazole powder in the amount of 0,521 kg is mixed with part of the molten core of witepsol taken in 1:1 ratio. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. The resulting concentrates are loaded into the remaining witepsol under stirring to obtain a homogeneous mass. The finished mass is poured into the cell from a polyvinylchloride film and cool.

Get suppositories weight of 2.35 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.4 g

Lomefloxacin 0.35 g

Metronidazole - 0.35 g

The basis is the steel.

Example 54.

Carried out analogously to example 53, but when the following quantities of components: complex bioregulatory peptides prostate cattle - of 0.081 kg, lomefloxacin - 0,244 kg metronidazole - 0,244 kg basics - 2,931 kg

Get suppositories weighing 2.15 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.05 g

Lomefloxacin - 0.15 g

Metronidazole - 0.15 g

The basis of the rest.

Example 55.

Carried out analogously to example 53, but when the following quantities of components: complex bioregulatory peptides prostate cattle - 0,622 kg, lomefloxacin - 0,233 kg metronidazole - 0,233 kg basics - 2,412 kg

Get suppositories weighing 2.25 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.4 g

Lomefloxacin - 0.15 g

Metronidazole - 0.15 g

The basis of the rest.

Example 56.

Carried out analogously to example 53, but when the following quantities of components: complex bioregulatory peptides prostate cattle - 0.077 kg, lomefloxacin - 0,544 kg metronidazole - 0,544 kg basics - 2,335 kg

Get suppositories weighing 2.25 g, having the following composition:

Complex bioregulatory peptides prostate W is Lesa cattle - 0.05 g

Lomefloxacin 0.35 g

Metronidazole - 0.35 g

The basis of the rest.

Example 57.

Carried out analogously to example 53, only as antibiotic product contains ofloxacin.

Example 58.

Carried out analogously to example 54, only as antibiotic product contains ofloxacin.

Example 59.

Carried out analogously to example 55, only as antibiotic product contains ofloxacin.

Example 60.

Carried out analogously to example 56, only as antibiotic product contains ofloxacin.

Example 61.

Carried out analogously to example 53, only as antibiotic product contains amoxicillin.

Example 62.

Carried out analogously to example 54, only as antibiotic product contains amoxicillin.

Example 63.

Carried out analogously to example 55, only as antibiotic product contains amoxicillin.

Example 64.

Carried out analogously to example 56, only as antibiotic product contains amoxicillin.

Example 65.

Carried out analogously to example 53, only as antibiotic product contains the ampicillin.

Example 66.

Carried out analogously to example 54, only as antibiotic product contains the ampicillin.

Example 67.

Carried out analogously to example 55, only as antibiotic product contains the ampicillin.

Example 68

Carried out analogously to example 56, only as antibiotic product contains the ampicillin.

Example 69.

Carried out analogously to example 53, only as antibiotic product contains cefaclor.

Example 70.

Carried out analogously to example 54, only as antibiotic product contains cefaclor.

Example 71.

Carried out analogously to example 55, only as antibiotic product contains cefaclor.

Example 72.

Carried out analogously to example 56, only as antibiotic product contains cefaclor.

Example 73.

Carried out analogously to example 53, only as antibiotic product contains cefixime.

Example 74.

Carried out analogously to example 54, only as antibiotic product contains cefixime.

Example 75.

Carried out analogously to example 55, only as antibiotic product contains cefixime.

Example 76.

Carried out analogously to example 56, only as antibiotic product contains cefixime.

Example 77.

Carried out analogously to example 53, only as antibiotic product contains doxycycline.

Example 78.

Carried out analogously to example 54, only as antibiotic product contains doxycycline.

Example 79.

Carried out analogously to example 55, only as antibiotic product contains doxycycline.

Example 80.

<> Carried out analogously to example 56, only as antibiotic product contains doxycycline.

Example 81.

Carried out analogously to example 53, only as antibiotic product contains the tetracycline.

Example 82.

Carried out analogously to example 54, only as antibiotic product contains the tetracycline.

Example 83.

Carried out analogously to example 55, only as antibiotic product contains the tetracycline.

Example 84.

Carried out analogously to example 56, only as antibiotic product contains the tetracycline.

Example 85.

Melt the basis of witepsol in the amount of UAH 1,862 kg at a temperature of 55-65°under stirring. Complex bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% in the number of 0,596 kg is mixed with part of the molten core of witepsol taken in 1:1 ratio. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. Powder antibiotic - lomefloxacin in the number 0,521 kg is mixed with part of the molten core of witepsol taken in 1:1 ratio. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. Antibacterial agent - tinidazole-in the form of powder in the amount of 0,521 kg is mixed with part of RASPLAV is on witepsol, taken in the ratio 1:1. Prepare a concentrate, rubbing the powder on a three-wheel rubbing machine to 40 μm is not less than 95%. The resulting concentrates are loaded into the remaining witepsol under stirring to obtain a homogeneous mass. The finished mass is poured into the cell from a polyvinylchloride film and cool.

Get suppositories weight of 2.35 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.4 g

Lomefloxacin 0.35 g

Tinidazole - 0.35 g

The basis of the rest.

Example 86.

Carried out analogously to example 85, but when the following quantities of components: complex bioregulatory peptides prostate cattle - of 0.081 kg, lomefloxacin - 0,244 kg tinidazole - 0,244 kg basics - 2,931 kg

Get suppositories weighing 2.15 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.05 g

Lomefloxacin - 0.15 g

Tinidazole - 0.15 g

The basis of the rest.

Example 87.

Carried out analogously to example 85, but when the following quantities of components: complex bioregulatory peptides prostate cattle - of 0.081 kg, lomefloxacin - 0,244 kg tinidazole - 0,244 kg basics - 2,931 kg

Get suppositories weighing 2.15 g, having the following composition:

Complexiresource peptides of the prostate gland of cattle - 0.05 g

Lomefloxacin - 0.15 g

Tinidazole - 0.15 g

The basis of the rest.

Example 88.

Carried out analogously to example 85, but when the following quantities of components: complex bioregulatory peptides prostate cattle - 0.077 kg, lomefloxacin - 0,544 kg tinidazole - 0,544 kg basics - 2,335 kg

Get suppositories weighing 2.25 g, having the following composition:

Complex bioregulatory peptides prostate cattle - 0.05 g

Lomefloxacin 0.35 g

Tinidazole - 0.35 g

The basis of the rest.

Example 89.

Carried out analogously to example 85, only as antibiotic product contains ofloxacin.

Example 90.

Carried out analogously to example 86, only as antibiotic product contains ofloxacin.

Example 91.

Carried out analogously to example 87, only as antibiotic product contains ofloxacin.

Example 92.

Carried out analogously to example 88, only as antibiotic product contains ofloxacin.

Example 93.

Carried out analogously to example 85, only as antibiotic product contains amoxicillin.

Example 94.

Carried out analogously to example 86, only as antibiotic product contains amoxicillin.

Example 95.

Carried out analogously to example 87, only as antibiotic product contains amoxi Illin.

Example 96.

Carried out analogously to example 88, only as antibiotic product contains amoxicillin.

Example 97.

Carried out analogously to example 85, only as antibiotic product contains the ampicillin.

Example 98.

Carried out analogously to example 86, only as antibiotic product contains the ampicillin.

Example 99.

Carried out analogously to example 87, only as antibiotic product contains the ampicillin.

Example 100.

Carried out analogously to example 88, only as antibiotic product contains the ampicillin.

Example 101.

Carried out analogously to example 85, only as antibiotic product contains cefaclor.

Example 102.

Carried out analogously to example 86, only as antibiotic product contains cefaclor.

Example 103.

Carried out analogously to example 87, only as antibiotic product contains cefaclor.

Example 104.

Carried out analogously to example 88, only as antibiotic product contains cefaclor.

Example 105.

Carried out analogously to example 85, only as antibiotic product contains cefixime.

Example 106.

Carried out analogously to example 86, only as antibiotic product contains cefixime.

Example 107.

Carried out analogously to example 87, only as antibiotic product contains Cefix the M.

Example 108.

Carried out analogously to example 88, only as antibiotic product contains cefixime.

Example 109.

Carried out analogously to example 85, only as antibiotic product contains doxycycline.

Example 110.

Carried out analogously to example 86, only as antibiotic product contains doxycycline.

Example 111.

Carried out analogously to example 87, only as antibiotic product contains doxycycline.

Example 112.

Carried out analogously to example 88, only as antibiotic product contains doxycycline.

Example 113.

Carried out analogously to example 85, only as antibiotic product contains the tetracycline.

Example 114.

Carried out analogously to example 86, only as antibiotic product contains the tetracycline.

Example 115.

Carried out analogously to example 87, only as antibiotic product contains the tetracycline.

Example 116.

Carried out analogously to example 88, only as antibiotic product contains the tetracycline.

Example 117.

Carried out analogously to example 53, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 118.

Carried out analogously to example 54, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 119.

Conducted similarly note the PN 55, only instead of the antibiotic product contains antiviral agent ribavirin.

Example 120.

Carried out analogously to example 56, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 121.

Carried out analogously to example 85, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 122.

Carried out analogously to example 86, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 123.

Carried out analogously to example 87, but instead of antibiotic tool contains the antiviral agent ribavirin.

Example 124.

Carried out analogously to example 88, only instead of the antibiotic product contains antiviral agent ribavirin.

Example 125.

Carried out analogously to example 53, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 126.

Carried out analogously to example 54, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 127.

Carried out analogously to example 55, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 128.

Carried out analogously to example 56, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 129.

Conducted analogichnimi 85, only instead of the antibiotic product contains antiviral agent lamivudine.

Example 130.

Carried out analogously to example 86, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 131.

Carried out analogously to example 87, but instead of the antibiotic product contains antiviral agent lamivudine.

Example 132.

Carried out analogously to example 88, only instead of the antibiotic product contains antiviral agent lamivudine.

Determination of water-soluble peptides carry out spectrophotometric method. Determination of antibiotic, in particular lomefloxacin, carried out by high performance liquid chromatography (HPLC) on a liquid chromatograph firms Waters (or similar) with a spectrophotometric detector.

Test for microbiological purity suppositories conducted in accordance with the requirements of the global Fund XI, issue 2, s and Changes No. 3, category 3A. The obtained results are in line with regulatory requirements.

Received suppositories have color from white or almost white to light cream color with grayish shade, torpedo-shaped form. In appearance suppositories satisfy the requirements of the global Fund XI, issue 2.

To determine the General toxic action and evidence of the effectiveness of PR is degenova funds were conducted its pre-clinical trials at the Central research laboratory of the Nizhny Novgorod state medical Academy in October 2004.

Testing was presented to the tool in the form of a suppository, containing as active substance complex of bioregulatory peptides of the prostate gland of cattle and lomefloxacin as antimicrobials. Component content in mg per one suppository presented in table 1.

Table 1
The composition of the proposed funds for one suppository mg
Complex bioregulatory peptides of the prostate gland of cattle (supresta substance (prostate extract)) (the Fund 42-0179-2983-02 or another, registered in the Russian Federation, similar quality) in terms of a 20% content of water-soluble peptides- 100
Lomefloxacin hydrochloride (ND 42-10824-00 or another, registered in the Russian Federation, similar quality)- 400
Bases for suppositories: Witepsol (TU 3-2004 or another, allowed the Russian Ministry of health for the production of medicines, similar quality)- a sufficient number to obtain the suppository mass of 2.25 g

Toxicological studies were performed in accordance with the recommendations of the "Manual on experimental (preclinical) and the teaching of new pharmacological substances", 2000.

Materials the experiments were subjected to statistical processing by the conventional method and the Student. The report presents experimental data obtained from 10-11 animals in each group.

Determination of the acute toxicity study rectal dosage forms is technically impossible and impractical in other ways.

The sub-chronic duration of the experiment for 30 days was chosen for the new combination used in clinical practice components.

Sub-chronic experiment was carried out in randombred white rats-males weighing 204±5, Animals were kept in plastic cages area of 2150 cm27-8 individuals in natural light mode, fed piketirovany and natural foods in accordance with the norms approved by the health Ministry.

All experimental animals were divided into 3 groups of 11 animals each. Groups were formed by random numbers using body mass as a leading symptom. Scheme of the experiment is given in table 2.

Table 2
Scheme sub-chronic Toxicological experiments on white rats
No. of groupsSex animalsThe number of animals in gr is the group Dose, mg/kgThe timing of reading out
1males1114 mg/kgBackground 1 month
2males11140 mg/kg
3males11Control

The proposed tool was administered rectally once daily, for 1 month at doses of 14 (therapeutic) and 140 mg/kg, ten times greater than therapeutic dose for rats and 70 times for the people in mg/kg Interspecies dose calculations performed by E.J. Freireich et al.

The General condition of the experimental animals was evaluated by appearance, behavioral reactions and integral parameters (feed and water intake, the dynamics of body weight).

The state of the cardiovascular system was studied using electrocardiography (ECG) in the second standard lead without anesthesia on ACCMP-N at a speed paper feed 200 mm/sec and under 1 mV - 20 mm

After 30 days of the introduction of the proposed tool, it did not cause statistically significant changes in studied parameters of the electrocardiogram in experimental animals (table 3, 4).

Table 3
The ECG cap is before the impact of the proposed tools (M± m; n=10)
No. groupFloorDose, mg/kgThe amplitude of teeth, mVThe duration of the interval, in secondsHR / min
PRSTPQQRSQTRR
114,00,103±0,0040,356±0,0210,017±0,0110,089±0,0050,0408±0,00080,0183±0,00040,0562±0,00110,1112±0,0012540,1±5,9
2140,0is 0.102±0,0040,376±0,0220,009±0,0090,094±0,0030,0389±0,00090,0187±0,00040,0568±0,00150,1122±0,0008535,0±3,6
3control0,103±0,0050,364±0,0290,045±0,0380,084±0,0050,0403±0,00090,0184±0,00060,0556±0,00150,1108 0,0015542,4±7,0
Table 4
The ECG parameters in rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgThe amplitude of teeth, mVThe duration of the interval, in secondsHR / min
PRSTPQQRSQTRR
114,00,096±0,0040,383±0,0160,024±0,0180,091±0,0060,0408±0,00090,0189±0,00060,0584±0,00120,1128±0,0013532,5±6,06
2140,00,197±0,0050,372±0,0240,021±0,0110,089±0,0070,0409±0,00120,0203±0,00040,0591±0,00140,1154±0,0011520,4±5,06
3controlis 0.102± 0,0030,386±0,0200,067±0,0330,087±0,0040,0415±0,00060,0196±0,00070,0583±0,00190,1136±0,0015529,0±7,08

Status of peripheral blood was judged by the number of erythrocytes and leukocytes (counting in the Goryayev camera), platelets (counting the blood smears) and reticulocytes count in the blood smears, stained diamond crazylove blue, leukogram - count in the blood smears stained by Romanovsky-Institute, hemoglobin (measurement in hemoglobinometry GF), parameters of blood coagulation (coagulogram H-334).

When the impact of the proposed funds for 30 days in the peripheral blood of rats of all experimental groups was not significantly different from the control side of investigated parameters (erythrocytes, leukocytes, hemoglobin, reticulocytes, platelets, WBC). The data presented in tables 5, 6.

Table 5
The state of the peripheral blood in rats prior to the introduction of the proposed tools (M±m; n=10)
No.123
Floor
Dose, mg/kg14,0140,0control
Hemoglobin, g/l121.00 amendment±3,75120,25±4.26 deaths118,50±3,65
Erythrocytes, t/l7,87±0,446,91±0,448,02±0,49
Color index0,797±0,0650,905±of 0.0660,764±0,050
The reticulocytes, %28,30±1,7629,00±1,9230,30±1,94
Platelets, g/l537,40±34,24449,62±31,85555,48±43,95
Leukocytes, g/l14,16±0,9712,94±1,0714,11±0,93
Leukogram (g/l)neutrophilsp/I0,214±0,0280,181±0,0260,198±0,029
C/I1,810±0,2891,818±0,2022,185±0,283
lymphocytes11,82±0,75of 10.73±0,9511,50±0,72
monocytesis 0.135±0,0490,129±0,0460,125±0,035
eosinophils0,188±0,0420,088±0,0440,101±0,030

Table 6
The state of the peripheral blood of rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No.123
Floor
Dose, mg/kg14,0140,0control
Hemoglobin, g/l127,40±4,63127,25±3,53127,40±4,01
Erythrocytes, t/l8,71±0,178,77±0,24a total of 8.74±0,23
Color index0,736±0,0350,715±0,0270,734±to 0.032
The reticulocytes, %24,20±1,8122,10±2,6723,70±2,62
Platelets, CH 584,55±16,97569,32±23,33573,62±21,83
Leukocytes, g/l16,99±0,3216,34±0,6316,38±0,59
Leukogram (g/l)neutrophilsp/I0,273±0,0290,212±0,0250,227±0,025
C/I2,544±0,1942,348±0,2732,043±0,210
lymphocytes14,01±0,2313,51±0,5013,85±0,50
monocytes0,050±0,0260,103±0,0460,147±0,052
eosinophils0,121±0,0270,166±0,0430,116±0,034

Within 30 days of the experiment the proposed remedy does not affect the status of the coagulation laboratory animals, according to the parameters of coagulation (table 7).

Table 7
The state of blood coagulation in rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgWith artisana, secThe rate of coagulation
StartEndDuration1 min2 minfor 3 min
114,0121,70±14,44305,70±13,89184,00±21,510.800 to±0,1250,420±0,1240,080±0,055
2140,0120,00±20,30279,00±60,06159,00±42,991,680±0,4030,510±0,2030,290±0,116
3control120,90±17,92300,30±24,03179,40±13,150,830±0,1660,690±of) 0.1570,210±0,142

Program of study General toxic effect of the proposed remedies included a set of tests to assess liver function. Secretory and absorptive functions of the liver was studied by BSF sample, velocimeters function on the content of total protein using the biuret reaction, lipid - content of total lipids by the colorimetric method with the reagent, consisting of vanillin and phosphoric acid, soda is a place of total cholesterol according to the method Ilka. The antitoxic function of the liver was assessed by duration "geksenalovy sleep.

The introduction of the proposed features for 30 days had no effect on the secretory, absorptive and velocimeters liver function in all animals tested (table 8, 9).

Table 8
The state of absorptive and excretory functions of the liver of rats after 30 days of the introduction of the proposed tools (M±m; n=10).
No. groupFloorDose, mg/kgThe retention of BSF in the blood (%)
114,014,53±0,29
2140,014,13±0,22
3control14,42±0,48
Table 9
The impact of the proposed funds for the concentration of total protein in serum of rats (M± m; n=10)
No. groupFloorDose, mg/kgTotal protein serum (g/l)
Prior to the introductionAfter 30 days of administration
114,085,20±2,5986,69±1,30
2140,085,07±2,0190,37±1,53
3control85,73±1,5788,34±1,62

Lipid liver function and glucose in the blood in all experimental groups did not differ from the control (table 10, 11).

After 30 days of administration
Table 10
The impact of the proposed funds for the content of total lipids in blood serum of rats (M±m; n=10)
No. groupFloorDose, mg/kgTotal lipids (g/l)
Prior to the introduction
114,02,542±0,1012,036±0,115
2140,02,553±0,0761,988±0,103
3control2,578±0,0911,939±0,116

Table 11
The impact of the proposed funds for the glucose content in blood serum (M±m; n=10)
No. groupFloorDose

mg/kg
Glucose serum (mmol/l)
Prior to the introductionAfter 30 days of administration
114,03,807±0,0,853,865±0,097
2140,03,759±0,1013,833±0,131
3control3,837±0,0983,702±0,112

The concentration of total cholesterol the serum of animals of all experimental groups offer a means had no significant influence (table).

Table 12
The impact of the proposed funds for the concentration of total cholesterol in serum of rats (M±m; n=10)
No. groupFloorDose, mg/kgTotal cholesterol (mm/l)
Prior to the introductionAfter 30 days of administration
114,01,81±0,081,82±0,08
2140,01,78±0,091,76±0,08
3control1,85±0,081,76±0,08

The antitoxic function of the liver, according to the duration geksenalovy" sleep in all experimental animals did not differ from the control (table 13).

Table 13
The state of the antitoxic function of the liver of rats (M±m; n=10)
No. groupFloorDose, mg/kgDuration geksenalovy" sleep, min
1img src="https://img.russianpatents.com/848/8486291-s.gif" height="5" width="5" > 14,022,60±2,17
2140,019,00±2,31
3control21,00±3,05

The functional condition of the pancreas and indirectly carbohydrate liver function was determined by the glucose content in the blood serum glucose oxydase method.

The function of the excretory system was investigated according to the following program: spontaneous diuresis for 18 hours, the specific gravity of urine by the gravimetric method, pH of urine, urea in serum and urine diacetylbenzene method with subsequent calculation of the standard coefficient of purification of urea (ISH); the content of creatinine in serum and urine by the Jaffe reaction and determination of creatinine clearance as a measure of glomerular filtration; the content of potassium and sodium ions in blood serum and their excretion in the urine by flame photometry on the PFM-1; load phenol red as an indicator of the secretory function of the kidneys.

Under the influence of the drug the functional state of the kidneys in all experimental animals was almost unchanged (table 14-20).

Table 14
The figures plot the positive system of rats prior to the introduction of the proposed tools (M± m; n=10)
No. groupFloorDose mg/kgDiuresis

for 18 h, ml
urine pH, edSpecific

weight

urine,

g/cm3
Concentration

urea

mm/l
Content

urea

in the urine,

mm/18 h
ISH
in CIV. bloodin urine
114,02,29±0,186,6±0,11,038±0,0037,00±0,1640,49±0,950,092±0,0060,264±0,008
2140,02,39±0,266,6±0,11,041±0,0027,39±0,1740,63±0,880,098±0,0110,257±0,018
3controlof 2.51±0,286,6±0,11,043±0,0037,20±0,1340,79±0,980,103±0,0130,270±0,018

0,322±0,029
Table 15
Indicators of the excretory system of rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose mg/kgDiuresis

for 18 PM, ml
urine pH, edSpecific

weight

urine,

g/cm3
Concentration

urea

mm/l
Content

urea

urine, mm/18

PM
ISH
in CIV. bloodin urine
114,03,410±0,4216,7±0,11,041±0,0017,08±0,1839,83±0,87is 0.135±0,0160,309±0,019
2140,03,140±0,3346,7±0,11,043±0,0027,15±0,1840,15±1,020,128±0,0160,301±0,021
3control3,640±0,4996,8±0,11,041±0,0027,22±0,1740,40±0,760,148±0,021

Table 16
The state of the secretory function of the kidneys of rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgThe excretion of phenol red, mg/2 hours
114,040,18±1,64
2140,039,77±1,71
3control38,23±0,86

Table 17
Indices of mineral metabolism of rats prior to the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgPotassiumSodiumNa+/K+
serum, mmol/lUrineserum, mmol/lUrine
mm/18 hmm/18 h
114,06,60±0,160,49±0,05167,04±5,160,43±0,0525,3/1
2140,06,59±0,360,47±0,06170,52±4,140,45±0,0725,8/1
3control6,50±0,310,52±0,06173,13±4,930,50±0,0726,6/1
Table 18
Indices of mineral metabolism of rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgPotassiumSodiumNa+/K+
serum, mmol/lUrine serum, mmol/lUrine
mm/18 hmm/18 h
114,06,44±0,340,66±0,09179,18±6,360,97±0,1427,8/1
2140,06,44±0,340,60±0,07187,05±7,700,89±0,0829,0/1
3control6,60±0,390,69±0,11182,74±6,600,98±0,1627,7/1
Table 19
Glomerular filtration of the kidneys of rats prior to the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose, mg/kgThe diuresis for 18 h, mlConc is tion creatinine Creatinine clearance, ml/min
in serum, m/lin the urine, mm/l
114,02,29±0,1869,60±2,1610,26±0,240,3163±0,0284
2140,02,39±0,2670,76±2,779,98±0,260,3124±0,0327
3controlof 2.51±0,2871,34±2,94of 10.21±0,180,3346±0,0377

Table 20
Glomerular filtration of the kidneys of rats after 30 days of the introduction of the proposed tools (M±m; n=10)
No. groupFloorDose mg/kgThe diuresis for 18 h, mlCreatinine concentration Creatinine clearance, ml/min
in serum, m/lin the urine, mm/l
114,03,67±±0,4471,66±3,6210,29±0,160,4832±0,0541
2140,03,14±0,3370,52±3,299,95±0,240,4035±0,0360
3control3,64±0,50to 73.65±2,07accounted for 10.39±0,250,4750±0,0658

The functional state of the nervous system was assessed by the method of "open field" on Boisse own modifications on spontaneous locomotor activity, which was recorded using actometry firm Ugo Basile" and summation threshold indicator.

30 days after the beginning of the introduction of the parameters "open field" was not significantly different from the control (table 21, 22).

Table 21
Functional indicators of the condition of the nervous system of rats prior to the introduction of the proposed tools (M±m; n=11)
No. the group 123
Floor
Dose, mg/kg14,0140,0control
Open fieldThe intersection of the squares46,0±9,437,4±4,863,5±13,1
Hours14,8±2,310,2±2,418,5±4,0
Washing2,8±1,05,0±0,74,6±0,9
Cleaning1,4±0,41,7±0,72,3±0,6
The shaking2,1±0,61,3±0,60,9±0,4
Defecation4,3±0,54,7±0,74,6±0,5
Mink reflex1-5 min4,2±1,03,5±1,68,2±2,0
6-10 min2,6±1,31,4±0,83,0±0,9
10 min6,8±1,94,8±2,311,2±2,6

Table 22
Functional indicators of the condition of the nervous system of rats after 30 days of the introduction of the proposed tools (M±m; n=11)
No. groupFloorDose mg/kgOpen fieldMink reflex
The intersection of the squaresHoursWashingCleaningThe shakingDefecation1-5 min6-10 min10 min
114,047,7±11,99,3±2,03,4±0,71,3±0,61,1±0,62,7±0,61,8±0,62,0±0,63,2±0,9
2140,045,2±14,59,9±3,13,7±0,81,3±0,71,1±0,63,3±0,61,5±0,91,5±0,62,9±1,4
3control30,9±12,58,3±2,41,8±0,6 1,1±0,51,4±0,73,4±0,81,0±0,41,6±0,72,6±0,9

After 1 month of introduction of the proposed funds total motor activity and emotional condition did not significantly differ from control. The data are shown in table 23.

Table 23
The impact of the proposed remedies on the locomotor activity of rats (M±m; n=11)
No. groupFloorDose, mg/kgLocomotionDefecation
Before the introduction ofAfter 14 days of administrationBefore the introduction ofAfter 14 days of administration
114,0173,45±10,91127,09±17,433,09±0,732,55±0,59
2140,0162,27±8,90120,45±20,563,91±0,723,64±0,64
3control188,18±17,43165,27�B1; grade of 20.062,36±0,961,82±0,92

The proposed tool after 30 days rectal injection did not cause significant changes in the WBS (table).

Table 24
The impact of the proposed means for summation-threshold indicator rats (M±m; n=11)
No. groupFloorDose, mg/kgSummation-threshold indicator
Before the introduction ofAfter 30 days of administration
114,03,75±0,153,42±0,14
2140,03,95±0,163,65±0,23
3control3,76±0,103,36±0,17

During the experiment, mortality was not observed. Examination of the animals revealed that all of them are normally well-fed, have the correct shape, neat hair and natural orifice clean.

Upon completion of the experiment, experimental animals were slaughtered (decapitation), dissected, defined the Yali relative mass of bodies.

By visual examination during autopsy, from the internal organs of the significant differences in experimental and control rats were not identified. The bodies are correctly positioned, free fluid in the thoracic and abdominal cavities no. Visual signs of pathology of organs and tissues was not found.

The heart muscle and valves unchanged. The Lumina of the trachea and large bronchi free. The light fabric of the air, pink color, with no signs of edema. The mucous membrane of the stomach, duodenum 12, small and large intestines, Appendix without ulcerations and hemorrhages. The capsule of the kidney is removed easily, in the context of cortical and brain chemistry is distinct. Thymus gray-pink color, not increased. The thyroid gland is pink in color with distinct parathyroid gland. The adrenal glands intact. Shell brain is not strained, gyrus is well expressed. Genitals without any deviations.

For pathomorphological studies were taken from experimental animals of all groups of the following organs: brain, heart, lymph nodes, spleen, thyroid and parathyroid glands, thymus, adrenal glands, pituitary gland, stomach, intestine, pancreas, liver, lungs, kidneys, testes, prostate gland.

The determination of the relative masses of the bodies of experimental stomach what's revealed no significant differences from control at the impact of the proposed funds in specified doses (table).

Table 25
The relative weight of organs of rats in the experiment on the study of General toxic effect of the proposed tools (M±m; n=10)
No.123
Floor
Dose, mg/kg14,0140,0control
The ratio of the weight of organs to body weight (%)Liver3,76±0,16a 3.87±0,123,71±0,10
Heart0,380±0,0170,383±0,0140,356±0,013
Spleen0,588±0,0440,494±0,0450,501±0,055
Kidneyleft0,402±0,0170,403±0,0070,392±0,015
right0,401±0,0160,403±0,0070,384±0,014
The adrenal glandsleft0,0137±0,00230,115± 0,00060,0101±0,0007
right0,0155±0,00220,0137±0,00130,0113±0,0010
Testesleft0,5165±0,01880,5229±0,02010,5111±0,0199
right0,5169±0,01740,5227±0,01730,5137±0,0199
Thyroid gland0,0066±0,00110,0076±0,00080,0080±0,0003
The brain0,618±0,0250,679±0,0190,661±0,033
The pituitary gland0,00347±0,000080,00352±0,000140,00356±0,00019

Morphological structure of the studied organs of the control animals corresponds to the norm.

Compared with the control group of animals of the 2nd group (140 mg/kg) showed a small macrophage reaction in the brain layer lymph nodes, well-defined reactive centers.

In the adrenal glands small and moderate venous plethora brain layer.

In the introduction, the proposed means no pathological changes.

For the study of the specific pharmacological action of the proposed funds in the form of rectal suppositories were conducted experimental the options using adult outbred white rats (kennel "High" SE NTS BMT RAMS). The animals comply with the rules of the organization, equipment and maintenance of experimental biological clinics (vivarium). Feeding the animals natural and piketirovany feed in accordance with the approved standards. Animals were quarantined and acclimatized in vivarium conditions for 14 days. Experimental groups of animals were formed by random sampling taking into account body mass as a defining parameter.

The experiments were carried out in October 2004

The procedure of identification of individuals: marking animals in groups was performed using nadreck on the ear and coloring dyes (eosin methylene blue) surface of the tail on the developed schemes, according to the available guidelines.

The method of euthanasia of animals: decapitation.

The number of animals in study groups - 10.

To evaluate the effectiveness studied the effect of the proposed remedies in case of rectal administration. The proposed tool was introduced in the form of a specially made small rectal suppositories containing active and auxiliary substances in the appropriate dosage, embedded in the normative documentation on this drug. As a control substance by rectal application was used suppositories, specially manufactured is blennie of the fundamentals of medicines.

Rectal suppositories were administered to rats once a day, 1 after emptying.

Selection of doses for the study was carried out taking into account the expected rate of application of the tools of man. The duration of administration of the medicinal product to the animals during the experiment amounted to 10 days.

When calculating doses proceeded from a daily dose of the drug Lomefloxacin: 400 mg per person weighing 70 kg and taking into account the conversion factor on rat 5,9. Thus equitisations dose lomefloxacin is: 400/70·5,9=33,7 mg/kg

Specific pharmacological action of the drug is studied in the simulation septic prostatitis in rats.

Before conducting the simulation prostatitis determined bakteriostaticescuu and bactericidal activity of the drug in the test in vitro. To determine the severity of the bactericidal effect of the drug in vitro systems, studied its effects on sensitive organisms specified in the regulations of the manufacturer. In our experiments we used the standard strains: Staphylococcus aureus strain 7M (NIEM, N.Novgorod) and Esherichia coli strain 18M (Department of Microbiology and immunology, GOU VPO Nigga).

For growing staphylococci and Escherichia coli were used meat-peptone broth (BCH) and meat-peptone agar (MPA). Suspension of microorganisms containing 10 microbial cells in 1 ml (initial concentration) were prepared by flushing buffered saline (pH 7,2-7,4) 24-hour agar culture. Standardization of microbial suspensions was carried out according to the turbidity standard State control Institute of medical biological preparations behalf Laurasia for bacteria.

The study of bactericidal and bacteriostatic activity was carried out according to the previously mentioned recommendations in your own modifications.

The method of serial dilutions. Cooked breeding material suppositories in a nutrient medium. For this purpose, the drug was dissolved in meat-peptone broth at a ratio of 1:30. In tubes with the medium (3 ml)containing the drug and no drug (control), were made of 0.3 ml of a suspension of microorganisms to obtain different final concentrations (1·107, 1·106, 1·105, 1·104, 1·103). The tubes were incubated (37°C, 24 h). All the experiments were held in 3 repetitions. Take into account the tubes, which have seen the growth of microorganisms.

Diffusion method. The method used for detection of bactericidal activity of native substances rectal suppositories on Esherichia coli is one of the leading agents of pyogenic infections. Poured a simple agar in Petri dishes (20 ml per Cup). After hardening, in which the center of the agar punched 4 holes (5 mm diameter). On the surface of the agar was placed 0.1 ml suspension Esherichia coli strain 17M (initial concentration 1·109and planted a solid lawn method Drygalski. Then to each well was made on 100 mg suppositories. Cups with agar thermostatically (37°C, 24 h). The results were taken into account by measuring the diameter of zone (mm) delayed fungal growth around the wells with the drug. All experiments were made in three repetitions. Based on average results of the experiments.

To simulate septic prostatitis were selected microorganisms Escherichia coli as the most likely causative agents of infectious prostatitis, because it is much less common are the other members of the family Enterobacteriaceae and Pseudomonas sp.

As the material for the infection used, the suspension is sensitive to the drug (according to in vitro tests) Esherichia coli strain 18M in physiological solution (1·109CFU/ml). Used for the experiment felt disks sizes 2×1×1 mm was immersed in a physiological solution with a suspension of bacteria. Under Nembutal anesthesia (40 mg/kg) operation was implemented with the opening of the abdominal cavity of experimental animals and podlivaniem felt disk saturated with microorganisms, to the prostate gland. After 3 days developed septic prostatitis, and in experimental groups began treatment offered means is m, the rectal suppositories (OAO Nizhpharm, Russia); the treatment was conducted for 10 days. After completing a full course of treatment, the animals took a biopsy of the prostate (100 mg tissue) and carefully rubbed and did dilution 1:10, 1:100 in sterile saline. Were seeded in 0.1 ml of the diluted suspension on selective agar Endo method Drygalski (solid lawn). All experiments were made in three repetitions. Based on average results of the experiments. Counting the number of CFU E. coli after incubation (24 h, 37°).

Assessment of the status of animals and the development of experimental prostatitis without treatment and the treatment was carried out daily for the appearance settings of animals, and on the 3rd, 7th and 14th day of development prostatitis parameters of body weight, analysis of phagocytic activity of blood cell count and leukocyte formula, total protein content in serum, pathomorphological studies of the prostate.

Analysis of the phagocytic activity of the blood was carried out using the method Lomonosovskiy chemiluminescence. The method is based on the release of active forms of oxygen-stimulated cells. A bright flash of chemiluminescence accompanied by the reaction of interaction lyuminola with hypochlorite. Largest integral indicator S (sutasoma) estimated the number of educated the Orme oxygen, this value is proportional phagocytic activity.

As phagocytosis stimulator was used latex with a particle diameter of ˜1 μm. Prior to analysis 48 mg lyuminola was dissolved in 1 ml of 0.1 n KOH. After dissolution was brought to 100 ml with distilled water. The next day was filtered through a paper filter. Whole heparinized blood was diluted 100 times (Hanks solution without dye). Latex before use laundered to transparent nadeshiko. Take 1 ml of the latex mixture was added 10 ml of Hanks solution without dye and centrifuged at 3000 rpm for 15-20 minutes

During poured 0.7 ml of diluted blood and 0.1 ml of the primary solvent. Later in the cuvette in the sample compartment was added 0.2 ml lyuminola, 0.002 ml of latex. The measurement was carried out for 15 min, each sample on the instrument while BCL equals thousandth points-06", combined with PC. During this time occurred the registration peak and calculating the area under the peak (indicator S) using specialized software LUM. The peak was recorded in the interval of 5-10 min from the start of stimulation and reflect the full phagocytic response.

Phagocytic activity was evaluated in the values of S-integral total setosum.

To study the structure of the prostate (chronic prostatitis and treatment at the end of the experiment the prostate was dissected and fixyou and a 10% solution of neutral formalin for 48 hours. After fixing the prostate specimens were washed in running tap water for 12 hours and were dehydrated in ascending alcohols concentration. After dehydration, the tissue samples was performed through an intermediate medium (a mixture of 100° ethanol + chloroform = 1:1, chloroform + paraffin = 1:1), was soaked in 2 servings of paraffin at t=60°With and embedded in paraffin "Reservoir 54". Slices with a thickness of 5-7 μm was prepared on a sledge microtome Leica SM 2000R, putting on fat-free mixture Nikiforova (100° alcohol + ethyl ether = 1:1) glass slides were dried in a thermostat at t=37°C for 24 hours. After deparaffinize the sections were stained with hematoxylin and eosin, obezvozhivani in ascending alcohols concentration was prosvetlili in xylene and were concluded in canadian balsam. Ready histological specimens were kept in a horizontal position for 24 hours before drying of the resin and viewed using a light microscope Leica DMLS at magnification 100 and 200.

Methods of statistical data processing. The obtained results were processed on an IBM PC/AT using the software packages Statistica 6.0. The probability of differences in average in the groups was determined using the criterion t-Student. The differences were considered significant at a significance level of p<0,05.

Results and their discussion.

1. Biocidal action featur is imago funds in the form of rectal suppositories test in vitro

The results of microbiological studies are presented in tables 26 and 27.

Table 26
The impact of the proposed funds for Staphylococcus aureus and Esherichia coli.
Meat-peptone broth (BCH) with the proposed toolBCH without the proposed tools (control)
The final concentration of bacteria in the environment107106105104103107
The growth of S.aureus 7M-----+
The growth of Esherichia coli 18M-----+
"-" - absence of visible growth of microorganisms
"+" - the presence of microorganisms in the environment

According to the regulations of studies to identify biocenose drugs, the minimum inhibitory concentration of antimicrobial drug is breeding, the vast growth of microorganisms at a concentration of 104cells/ml and above. As can be seen from table 26, working dilution predlagaemoj the means 1:50 had a pronounced bactericidal effect against gram-positive and gram-negative flora, inhibiting the growth of Staphylococcus aureus and Esherichia coli at a final concentration of up to 107cells/ml

Data diffusion test (table 27) also confirmed significant bactericidal activity of native products in relation to strain Esherichia coli, which was subsequently used to infect laboratory animals, with the aim of creating a model of chronic prostatitis.

Table 27
Bactericidal activity of native substance of the proposed remedies in respect of Esherichia coli
The diameter of the zone of delayed growth (mm) near wells containing:
1. 100 mg money2. Empty pit (control)
44,6±3,6No stunting (solid growth Esherichia coli on agar)
p2-1<0,05

Thus, the proposed tool has a pronounced bactericidal activity in vitro systems as against gram-positive bacteria (Staphylococcus aureus), and gram-negative bacteria (Escherichia coli).

2. The study of the bactericidal action of the proposed tools for modeling bacterial chronic prostatitis

The results of microbiological investigations of prostate after treatment, smear the territorial prostatitis proposed remedy presented in table 28.

Table 28
The number of Esherichia coli in the material of the prostate after application of the funds within 10 days
The investigated groups of animals:The number of Esherichia coli on agar Endo (CFU per Petri dish)
A dilution of 1:10A dilution of 1:100
1. The control group935,4±65,663,3±14,7
2. After treatment, the proposed remedy466,3±93,427,6±5,8
p2-1<0,05p2-1<0,05

According to in vivo tests (table 28), after applying the treatment on offer means there is a decrease in the number of CFU in the drilled material. Presence although less than in the control of bacterial material in the prostate after treatment for 10 days, due to the peculiarities of modeling disease in rats (infection with high doses of Escherichia coli, the preservation of the source of infection in the abdominal cavity, the anatomical features of the rats).

Thus, the treatment offered by the facility within 10 days, almost 2 times reduces the number of bacteria (Escherichia coli) in prostate tissue, which indicates n is the existence of bactericidal effect of the proposed remedies in vivo.

3. The study of anti-inflammatory and organotropic action proposed tools for modeling bacterial prostatitis

In the treatment of bacterial prostatitis, caused by Escherichia coli, revealed a positive effect of the proposed drug on the external condition of the animals, food consumption, behavior. The difference in weight gain was accurate at the 4th day of treatment offered by the tool compared with the control series (table).

Table 29
Change of body weight of the rats in the experimental modeling of bacterial prostatitis and treatment offered by the tool (M±m)
Groups of animalsThe source dataThrough 3 days after the operation (start of treatment)The 4th day of treatment (7 days development of the prostate)After 10 days of treatment (the 14th day of development of the prostate)
1. Control250,21±5,3247,36±5,13232,00±4,80259,84±7,43
2. The proposed tool251,3±4,51258,80±4,86254,04±4,96263,32±7,47
p2-1<0,05

The dynamics of f is alternas activity against bacterial prostatitis and its treatment offered by the tool are presented in table 30.

Table 30
Phagocytic activity of blood (Rel. units) in the treatment of bacterial prostatitis in rats offered by the tool (M±m)
Groups of animalsThe source dataThrough 3 days after the operation (start of treatment)The 4th day of treatment (the 7th day of development of the prostate)After 10 days of treatment (14 days development of the prostate)
1. Control118,2±3,2242,96±3,2289,43±3,3164,2±8,1
2. The proposed tool114,2±4,8of 230.5±4,5*157,3±5,6122,5±4,2
p2-1<0,05p2-1<0,05

It is revealed that rectal application of the proposed tools for modeling bacterial prostatitis, caused by Escherichia coli, causes a decrease in phagocytic activity already on the 4th day of treatment compared with the control series and completely normalizes the activity of the inflammatory process after 10 days of treatment.

Thus, the proposed tool has a pronounced anti-inflammatory action according to the phagocytic activity.

Study the dynamics of hematological parameters in the treatment of bacterial prostatitis offered by the tool, also showed the presence of an effective therapeutic anti-inflammatory effect (table. 31).

Rectal application of the proposed tool after 10 days of treatment, i.e. on the 14th day of the current bacterial prostatitis, there was a reliable decrease in the percentage of neutrophils, monocytes, eosinophils, ESR compared with the control group.

Table 31
Change some hematological parameters in the application of the proposed remedies for the treatment of bacterial prostatitis (M±m)
Metric unitsGroups of animalsThe source dataThrough 3 days after the operation (start of treatment)The 4th day of treatment (the 7th day of development of the prostate)After 10 days of treatment (14 days development of the prostate)
Leukocytes (109)1. Control5,8±0,418,72±0,436,86±0,246,26±0,32
2. The proposed tool5,9±0,727,38±0,476,12±0,396,20±0,23
Neutrophils (%)1. Control20,1±0,3228,2±2,15 24,8±1,527,2±1,58
2. The proposed tool20,4±0,3331,4±1,7423,2±0,1721,2±0,89
p2-1<0,05
Lymphocytes (%)1. Control64,6±2,665,8±3,4370,6±2,1569,2±2,58
2. The proposed tool65,3±1,5669,4±3,070,8±4,5166,0±3,86
Monocytes (%)1. Control0,62±0,064,4±0,383,03±0,271,6±0,08
2. The proposed tool0,51±0,085,4±0,231,8±0,06

p2-1<0,05
0,41±0,03

p2-1<0,05
Eosinophils (%)1. Control1,5±0,023,4±0,093,4±0,933,2±0,36
2. The proposed tool1,6±0,033,2±0,272,6±0,171,6±0,01

p2-1<0,05
ESR, mm/hour1. Control2,05±0,0410,2±0,9910,6±0,78 3,2±0,19
2. The proposed tool2,1±0,0410,2±0,655,2±0,36

P2-1<0,05
2,0±0,08

p2-1<0,05

Thus, according to the hematological analysis, the proposed tool has anti-inflammatory action, providing a therapeutic effect in the development of bacterial prostatitis in rats.

Biochemical analysis total protein of blood serum in rats without treatment and after 10 days of treatment offered by the tool revealed an increase in total protein of blood serum in the group treated with the drug (table), which is likely to increase in the number of immunoglobulin in chronic infectious disease.

81,67±6,01
Table 32
The impact of the proposed funds for the total protein content (g/l) in serum of rats in the simulation chronic bacterial prostatitis
Groups of animalsThe source dataThrough 3 days after the operation (start of treatment)The 4th day of treatment (the 7th day of development of the prostate)After 10 days of treatment (14 days development of the prostate)
1. Control58,23±2,3588,00±1,9278,20±1,59
2. Medication60,2±2,1284,80±2,3775,80±1,3968,40±1,29
p2-1<0,05

Data pathomorphological studies. The application of the proposed tool leads to the elimination of signs of inflammation in the body: to reduce interstitial edema, restore secretory functions of the epithelium.

In the study of patterns of prostate control animals at 14 days of bacterial prostatitis there was marked interstitial edema, diffuse infiltration of leukocytes and lymphoid-cell elements in strips of connective tissue and the lumen of the end regions of the thyroid gland, the plethora of the vascular bed. Impaired secretory function of the gland, resulting in atrophy of the secretory epithelium, no secret in the end sections.

Treatment of animals offered by the tool led to the elimination of signs of inflammation in the body. In the parenchyma of the prostate was noted as areas of cancer with increasing height of epithelial layer and surface, and areas with integral departments, filled with secret and lined with prismatic and cubic epithelium. At the same time, the identified individual sites of edema of the stroma and the presence of dininig of cells in the glands secret.

Specific pharmacological action of the proposed tool has been studied for modeling bacterial prostatitis in rats and in vitro.

In tests in vitro proposed tool has a strong bactericidal action.

Exchange rectal administration proposed funds within 10 days resulted in a normalization of the function of the prostate, reduce inflammation, as evidenced by the decrease in phagocytic activity of the blood, a decrease in the total protein of blood serum, a decrease in the percentage of neutrophils, monocytes, eosinophils, ESR, reducing signs of inflammation in the body: the reduction of interstitial edema, restore secretory functions of the epithelium.

As studies have shown, the proposed tool in the form of a suppository has a high level organotropic activity and a high level of antimicrobial action.

1. For the treatment of diseases of the prostate, performed in the form of a suppository containing complex bioregulatory peptides of the prostate gland of cattle in the form of a powder containing the water-soluble peptides of at least 20% and a base, characterized in that it additionally contains an antimicrobial agent that represents the antibiotic or antiviral agent from a group with whom teticheskikh of nucleoside analogues or antibacterial agent, or a mixture of antibiotic and Antiprotozoal drugs are taken in the ratio 1:1, or a mixture of antiviral from the group of synthetic analogues of nucleosides and antibacterial means, taken in the ratio 1:1, in the following ratio of components, g on one candle:

Complex bioregulatory
peptides of the prostate
cattle0,05-0,4
Antimicrobial agentNot more than 0.7
BaseEnough
to obtain suppository
mass of 2.15 to 2.35.

2. The tool according to claim 1, characterized in that as an antibiotic it may contain an antibiotic from the group of fluoroquinolones, in particular lomefloxacin, ofloxacin, or from the group of penicillins, including amoxicillin, ampicillin, or from the group of cephalosporins, in particular, cefaclor, cefixime, or from the group of tetracyclines, particularly doxycycline, tetracycline, or from the group of the sulfonamides, in particular cotrimoxazole.

3. The tool according to claim 1, characterized in that as antiviral agents from the group syntheti the ski of nucleoside analogues it contains, in particular, ribavirin, lamivudine.

4. The tool according to claim 1, characterized in that as Antiprotozoal drugs it contains antibacterial drug from the group of nitroimidazoles, in particular metronidazole, Ornidazole, tinidazole.

5. The tool according to claim 1, characterized in that refers to any pharmaceutically acceptable basis for obtaining suppository, in particular witepsol, tallow, cocoa butter.



 

Same patents:

FIELD: microbiology.

SUBSTANCE: the resent innovation deals with mixing pertussis component, diphtheric and tetanus anatoxins and sorption of the mixture upon aluminum hydroxide followed by dosing the mixture into the tank, freeze drying the mixture and hermetic sealing of this tank, moreover, as pertussis component one should apply cell-free pertussis anatoxin; as for mixing cell-free pertussis anatoxin, diththeric and tetanus anatoxins it should be carried out simultaneously at availability of phosphate-buffered physiological solution; the mixture obtained should be kept for 1 h at about 4-10°C with subsequent sorption upon aluminum hydroxide; just before freeze drying the mixture should be supplemented with saccharose up to final concentration being 9-10.5%, then the mixture should be mixed and kept at about 4-10C for 1 h. The innovation enables to achieve decreased reactogeneity.

EFFECT: higher efficiency.

2 ex, 4 tbl

FIELD: medicine, pediatrics, obstetrics.

SUBSTANCE: method involves administration of preparations balans-narine-f and calcemin. Carrying out this therapy provides decreasing the content of staphylococci in breast milk, increasing the sterility period of milk based on reducing cellular membranes penetrability and to diminish probability in development complications in treatment of bacteriolactia in nursing women. Invention can be used in treatment of staphylococcus bacteriolactia in women.

EFFECT: improved method of treatment.

1 tbl, 2 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to phenylpyridazine derivative of general formula I , wherein R1 represents C1-C12-alkyl optionally comprising cyclic C3-C6-alkyl structures and optionally substituted by phenyl, which may be substituted by 1-2 halogen atoms; or C1-C12-alkenyl substituted by optionally halogen-substituted phenyl; R2 and R3, independently form each other, represent hydrogen, C1-C12-alkyl, C1-C12-hydroxyalkyl, C1-C12-dihydroxyalkyl, or C1-C12-alkynyl; or R2 and R3, together with adjacent nitrogen atom form 5-6-membered saturated heterocyclic group containing 1-2 nitrogen atoms and optionally oxygen atom, indicated heterocyclic group being optionally substituted by C1-C12-alkyl group, C1-C12-alkoxydicarboxylic group or phenyl-C1-C7-alkyl group; X, Y, and Z, independently form each other, represent hydrogen, halogen, optionally halogen(s)-substituted C1-C12-alkyl, C1-C12-alkoxy, C1-C12-alkylthio, C1-C12-alkylsulfinyl, C1-C12-alkylsulfonyl, or phenyl; and n is a number from 0 to 5; provided that R2 and R3 cannot be simultaneously hydrogen atoms or identical C1-C3-alkyl groups when R1 is benzyl or C1-C3-alkyl group; and salts of compounds I. Foregoing compounds manifest inhibitory activity against production of interleukin IL-1β being well dissoluble in water and characterized by good oral absorption. Invention also relates to therapeutical agent inhibiting production of interleukin 1β, pharmaceutical composition, employment of above-defined compounds, a method for treating disease caused by interleukin 1β production stimulation as well as methods for treating immune system disturbances, inflammatory conditions, ischemia, osteoporosis, or septicemia using above compounds.

EFFECT: expanded therapeutical possibilities.

22 cl, 4 dwg, 2 tbl, 217 ex

FIELD: medicine, gynecology, urology.

SUBSTANCE: on isolating Chlamydia out of infection foci and setting a preliminary diagnosis it is necessary to determine their sensitivity to different etiotropic preparations. Then it is important to sample a patient's blood followed by centrifuging and dividing it into plasma, erythrocytic mass and leukocytic suspension. Removed blood plasma should be substituted with physiological solution, and autoerythrocytes should be returned for a patient in physiological solution intravenously by drops. Autoleukocytic suspension should be activated with laser radiation of He-Ne laser at λ=0.63 mcm. Then it should be supplemented with etiotropic preparation moxyfloxacin to be intravenously injected for a patient. The procedure should be repeated daily for about 10-12 d. The innovation suggested enables to shorten the terms of interrupting the main clinical manifestations of the disease due to a purposeful transport of etiotropic preparation being of higher bacteriological efficiency in leukocytes activated with laser radiation, into primary (urogenital tract) and secondary (extraurogenital) foci of inflammation and, also, decrease side action of chemopreparations due to decreasing their course dosage.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: veterinary medicine.

SUBSTANCE: vaccine comprises as antigens cell suspension of pure cultures of a streptococcosus pathogen Streptococcus pneumoniae and an enterococcal pathogen Streptococcus fecalis isolated from suspension and prepared from damages organs of dead nutrias from the local epizootic focus wherein these cultures are grown separately in beef-extract broth with glucose with the concentration of microbial cells 4-5 billions in 1 cm3 and mixed in equal ratio. Also, vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumoniae isolated from a local epizootic focus in the nutrient medium with a titer 4-5 microbial cells in 1 cm3, 38.0-41.5; cell suspension of pure culture of enterococcal infection pathogen Streptococcus fecalis isolated from a local epizootic focus in the nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 38.0-41.5; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Vaccine is harmful and possesses high specificity and effectiveness.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: veterinary science.

SUBSTANCE: on finishing the lactation one should inject once antimicrobial preparation "Difumast" per 5 ml into all udder lobes and, additionally, intramuscularly one should inject immunomodulating "preparation "Dostim" at the dosage per 25 ml for the first time, and in 40-45 d - the second. The innovation enables to shorten the quantity of "difumast. The innovation enables to shorten the quantity of "Difumas" injected.

EFFECT: higher accuracy of prophylaxis.

1 tbl;, 1 ex

FIELD: medicine, oncology, biochemistry, antibiotics.

SUBSTANCE: invention relates to variants used in treatment of cancer. Method involves administration in a patient needing with such treatment of the effective dose of 9-amino-6-deoxy-5-hydroxytetracycline or its salt, or 9-nitro-6-deoxy-5-hydroxytetracycline or its salt for aims in treatment of breast cancer, melanoma, myeloma and prostate gland cancer. Invention provides anti-tumor, anti-metastatic effect and the elevating viability index based on inhibition of matrix-destructing metalloproteinase by indicated derivatives of tetracycline and without significant body weight loss.

EFFECT: valuable medicinal properties of derivatives, enhanced effectiveness of treatment.

4 cl, 5 tbl

FIELD: organic chemistry, antibacterial agents.

SUBSTANCE: invention relates to an agent used against acid-resistant microorganisms containing derivative of pyridone carboxylic acid as an active component, its pharmaceutically acceptable salt or its hydrate that elicits high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms. Invention describes agent used against acid-resistant microorganisms containing compound represented by the following formula (I) its salt or its hydrate as an active component wherein R1 represents cyclic alkyl group comprising 3-6 carbon atoms that can comprise substitute(s) chosen from halogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; A1 represents incomplete structure represented by the formula (2): wherein X2 represents halogen atom, alkyl group comprising 1-6 carbon atoms or alkoxy-group comprising 1-6 carbon atoms; A1, A2 and A3 form incomplete structure of the formula: in common with carbon atoms combined with them; X1 represents halogen atom; Y represents hydrogen atom; Z represents phenylpiperazine substitute. Invention provides synthesis of pyridone carboxylic acid eliciting high antibacterial activity against Mycobacterium tuberculosis and atypical acid-resistant microorganisms in combination with good pharmacokinetics indices and safety.

EFFECT: valuable biological property of agent.

10 cl, 9 tbl, 10 ex

FIELD: medicine, microbiology, clinical practice.

SUBSTANCE: claimed method includes determination of pectin antioxidant activity (AOA) by chemiluminescent method and on the base of AOA pectin bactericidal properties are evaluated, wherein increased AOA indicates increased bactericidal properties. Method of present invention makes it possible to decrease time of pectin antibacterial property determination from 3 days to 30 min.

EFFECT: method of decreased labor intensity and cost.

1 tbl, 1 dwg

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to a synthetic quinolone agent that is effective as medicinal agents, veterinary preparations, drugs used in fishing industry or as antibacterial preserving agents. Invention describes compound represented by the following general formula (I): as its separate isomers or their mixture, its salt and their hydrates wherein R1 represents cyclic alkyl group comprising 3-6 carbon atoms that can comprise a substitute chosen from halogen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; R4 represents hydrogen atom, amino-group, hydroxyl group; A represents nitrogen atom or part of structure as given in the invention claim; each R5 and R6 represents independently alkyl group comprising 1-6 carbon atoms or hydrogen atom; n means a whole number 1 or 2. Also, invention describes antibacterial agent and therapeutic agent based on compounds of the formula (I) used in treatment of infectious disease, a method for preparing antibacterial agent, a method for preparing a medicinal agent used in treatment of infectious disease and using compound of the formula (I) for preparing an antibacterial agent and using compound of the formula (I) for preparing a medicinal agent used in treatment of infectious disease. Invention provides novel compounds possessing useful biological properties.

EFFECT: improved preparing method of agents, valuable medicinal properties of compounds and agents.

35 cl, 2 tbl, 15 ex

FIELD: chemical-pharmaceutical industry.

SUBSTANCE: it has been suggested to apply a solid composition for manufacturing a pharmaceutical tablet or a suppository, its melting point being 25°C or higher and it contains an uninterrupted lipid component that contains either one or more than one galactolipids, one or more glyceride ether of fatty acids, possibly one or several out of the following: water and mono-triatomic alcohol at the quantity being up to 15 weight% against the weight of composition, and one or more agent chosen among pharmacologically active agent. The method for manufacturing the composition mentioned includes mixing galactolipids and glyceride ethers of fatty acids followed by dissolving pharmacologically active agents in a liquid phase, cooling up to a solid state and forming a tablet or a filled capsule. Pharmaceutical tablet or suppository are depicted that include uninterrupted lipid phase possibly containing an inert nucleus and, also, food tablets or suppositories of similar composition that include food agents instead of pharmacologically active agent and, possibly, having got one or more submembranes consisting of food excipients. The innovation provides economy and increased comfort in usage.

EFFECT: higher efficiency.

42 cl, 13 ex, 10 tbl

FIELD: microbiology, biotechnology, medicine, in particular production of living vaccines against viral infections.

SUBSTANCE: invention relates to living vaccines for rectal administration against viral infections based on attenuated recombinant Salmonella strains bearing protective viral antigens. Suppository for immunoprophylaxis of viral infections contains (per one 2 g suppository, mass %): cell slurry of attenuated recombinant Salmonella strains transformed with pGEX-2T-TBI, pcDNA-TCI, or pKHBc bearing gene of protective viral antigens, mixed with suppository base in amount of 106-109 living cells 1 %; fatty base 94 %; and emulsifier T2 5 %. As fatty solid cooking oil (94 %); or hydrolyzed cotton oil (94 %); or mixture of cooking oil (60 %), Cocoa fat (24 %), and solid wax (10 %).

EFFECT: agent for inducing of humoral and cell immune response to respective viral antigen.

8 tbl, 11 ex, 3 dwg

FIELD: medicine, gynecology, proctology, pharmacy.

SUBSTANCE: invention relates to medicaments made as vaginal and rectal suppository used in treatment of proctological, non-inflammatory and inflammatory diseases of female pelvis organs, among them complicated with suppurative-inflammatory processes. Invention relates to an agent used in treatment of gynecological and proctological diseases it is made as a suppository and comprises 2-ethyl-6-methyl-3-oxypyridine succinate as an active component and a base chosen from group involving polyethylene oxide-1500, polyethylene oxide-400, cacao butter and hydrogenated fats. Invention provides prolonged release of a curative preparation in mucosa and soft tissues and provides its effect for about 12 h. The procedure is suitable and easy in performance and can be carried out by patients independently under ambulatory conditions.

EFFECT: valuable medicinal and pharmaceutical properties of agent.

3 cl, 2 tbl, 2 ex

FIELD: pharmaceutical industry, in particular agent for prophylaxis and treatment of rheumatoid arthritis and osteoarthritis.

SUBSTANCE: disclosed are suppository having mass of 2-2.5 g containing (g): diclofenac 0.0225-0.0525; glucosamine hydrochloride 0.175-0.525; lecithin 0.057-0.063; and balance: solid fat.

EFFECT: agent for prophylaxis and treatment of arthritis, degenerative joint and backbone diseases with increased anti-inflammatory action and reduced ulcerogenic action.

1 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to the development of a novel vegetable-base agent that can be used in treatment of inflammatory diseases of small pelvis organs and diseases of rectum. Agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum comprises long turmeric (Curcuma longa L.) rhizome dried extract standardized by curcumin, anesthetic agent and pharmaceutically acceptable excipients. Agent is made as a suppository and comprises benzocaine as an anesthetic agent and vitepsol and cacao butter as a suppository base. Method for preparing agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves mixing long turmeric dried extract standardized by curcumin with anesthetic agent and a pharmaceutically acceptable excipient. Method for prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves using the proposed agent.

EFFECT: improved preparing agent, valuable medicinal properties of agent.

9 cl, 3 ex

FIELD: medicine, homeopathy, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates, in particular, to suppository possessing immunomodulating effect and comprising coneflower, accessory substances and a base, sea-buckthorn oil, arborvitae (thuja) homeopathic essence, baptisia homeopathic essence, Timalin-1C homeopathic trituratium wherein coneflower is a component of homeopathic essence. Suppository comprises anhydrous lanolin and wax as accessory substances and cacao butter as a base wherein components are taken in the definite ration in grams per one suppository of weight 2 g. Proposed suppository possesses the enhanced immunomodulating effect and allows stimulating processes of regeneration and hemogenesis and improves processes of cellular metabolism.

EFFECT: valuable medicinal properties of suppository.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: the present innovation deals with rectal suppositories that contain biphosphonic acids and their pharmacologically acceptable salts applied for preventing and treating diseases caused by affected calcium and magnesium balance in the body. The suggested new suppositories contain 0.1-10 weight% xydiphone and 0.5-10 weight emulsifiers, the rest - the foundation for one suppository of 1.125-2.5 g weight. Rectal xydiphone-containing suppositories could additionally contain medicinal and/or biologically active supplements, for example 0.1-1.0 weight% trisodium salt of phosphonoformic acid as medicinal additive, and, also, biologically active additive chosen out of the group of vitamin B6, B12 or carbon dioxide solution of common camomile, olive oil. The innovation provides the chance to avoid some complications occurred at applying this preparation in known forms and, also, in some cases leads to its increased efficiency.

EFFECT: higher efficiency of application.

4 cl, 4 ex, 1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to an agent used in treatment of rheumatic arthrosis and osteoarthrosis. Proposed suppository comprises glucosamine hydrochloride, 0.475-0.525 g, and solid fat or mixture of polyethylene glycols of molecular mass 1500 and 400 Da (95:5), the balance, per one suppository of mass 2.0-2.5 g. Invention provides enhancing bioavailability of glucosamine and decreases the level of allergic reactions.

EFFECT: improved and enhanced medicinal properties of composition.

2 ex

FIELD: veterinary science.

SUBSTANCE: preparation for treatment and prophylaxis of endometritis in cows comprises antibacterial substance dioxydin, gelatin, glycerol and distilled water wherein food or medicinal gelatin is used as gelatin source, distilled glycerol if the 1-st grade is used glycerol source and comprises additionally resorcinol and veterinary algalipin in the following ratio of components, g: dioxydin, 0.1-0.3; resorcinol, 0.01-0.02; veterinary algalipin, 0.9-1.1; food or medicinal gelatin, 1.5-2.0; distilled glycerol of the 1-st grade, 5.0-5.4, and distilled water, 2.1-2.6. Invention provides enhancing effectiveness of the preparation and fertilization in cows.

EFFECT: improved and valuable veterinary properties of preparation.

3 tbl

FIELD: veterinary pharmacology, veterinary science.

SUBSTANCE: the suggested method deals with mixing formalin with components followed by heating with subsequent cooling at the following ratio of components including: 0.8%-formalin 5 ml, analgin 1 g, Veratrum tincture 1.0 ml, glycerol 5 ml, citric acid 0.2 g, gelatin 3 g.

EFFECT: enhanced curative result, more convenient medicinal form.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves extracting means containing a substance possessing light hydrophobic properties negatively charged at alkaline pH from tissues being homologous to tissues under treatment. The substance has molecular mass of 500-15000 Da and is capable of reducing ratio of phosphorylated adenosine phosphate to atomic oxygen quantity consumed by high-energy mitochondria at oxidative phosphorylation stage.

EFFECT: enhanced effectiveness of treatment.

18 cl

Up!